-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Up to now, a total of 570 listed pharmaceutical companies in A-share and H-share markets have basically announced their 2022 mid-year report cards.
Overall, the growth rate of the entire pharmaceutical industry is slowing down, but IVD, CXO and innovation Companies in sub-sectors such as pharmaceuticals still performed relatively well
.
From the point of view of profitability, Jiu'an Medical's net profit in the first half of 2022 exceeded 10 billion yuan, and it performed well
.
Jiu’an Medical released its financial report for the first half of 2022 on August 29.
In the first half of the year, the company achieved revenue of 23.
267 billion yuan, a year-on-year increase of 3989.
07%; net profit attributable to the parent was 15.
244 billion yuan, a year-on-year increase of 27728.
49%; non-net profit attributable to the parent was 15.
286 billion Yuan, a year-on-year increase of 319,397.
92%
.
Among them, in the first quarter, the company achieved a net profit of 14.
312 billion yuan, a year-on-year increase of 37527.
35%
.
For the reason for the surge in performance in the first half of the year, Jiu'an Medical attributed it to the substantial growth in demand for antigen detection kit products in the United States
.
The company stated that its own brand "iHealth" conducts TOC sales through the website of its US subsidiary and Amazon's US e-commerce platform, and undertakes government orders and commercial orders
.
Due to the substantial increase in sales revenue of iHealth kit products during the reporting period, the company's performance during the reporting period also increased significantly compared with the same period last year
.
It is reported that iHealth received an emergency use authorization (EUA) in the United States in November 2021 and started sales
.
While Jiu'an Medical achieved outstanding performance, the stock price also rose.
The day after the interim report was disclosed, the stock price rose 8.
28% to close at 53.
35 yuan per share, with a total market value of 25.
685 billion yuan, an increase of 1.
965 billion yuan that day
.
It is worth mentioning that there is a huge gap between the second quarterly report and the first quarterly report
.
In this regard, Jiu'an Medical also issued a risk warning in the interim report, and uncertainty in the future may greatly affect the demand for kit products
.
The industry believes that this means that Jiu'an Medical, which relies heavily on the overseas business of iHealth kits, will experience weak growth in the company's performance once the order is fulfilled or there is no new major operating contract
.
The industry said that in recent years, domestic IVD companies have developed rapidly due to the impact of the environment, and the entire in vitro diagnostic industry has ushered in dividends.
The performance of Zan, Wanfu Bio, Wantai Bio, and Mingde Bio continued to rise sharply, but the growth rate of some companies has experienced a significant decline compared with the same period of the previous year, especially the related detection reagent products.
Products are more obvious, and the fatigue is gradually showing.
For example, ST Kehua, Rejing Bio, and Oriental Bio, the net profit attributable to shareholders of listed companies decreased by 90.
31%, 43.
17%, and 19.
23% year-on-year respectively
.
It is reported that under the current background, many enterprises have already accelerated their transformation, focusing on optimizing product structure and technologically superior products
.
For example, Shengxiang Bio has continuously expanded its product line based on its own research and development advantages in molecular diagnostic products; Wanfu Bio has wholly acquired Tianshen Medical based on the POCT concept to improve its product line in Xiaoguang, through the combination of products and channels , in order to play a better effect; Mingde Bio responded to investors on the interactive platform on September 6, saying that with the end of the epidemic in the future, the company's other business segments will recover demand, and the company's strategic focus will be readjusted to other than testing reagents.
Business sectors, including but not limited to immunodiagnosis, molecular diagnosis, blood gas diagnosis, coagulation diagnosis, etc.
, the above sectors are expected to bring new growth points for the company
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Overall, the growth rate of the entire pharmaceutical industry is slowing down, but IVD, CXO and innovation Companies in sub-sectors such as pharmaceuticals still performed relatively well
.
From the point of view of profitability, Jiu'an Medical's net profit in the first half of 2022 exceeded 10 billion yuan, and it performed well
.
Jiu’an Medical released its financial report for the first half of 2022 on August 29.
In the first half of the year, the company achieved revenue of 23.
267 billion yuan, a year-on-year increase of 3989.
07%; net profit attributable to the parent was 15.
244 billion yuan, a year-on-year increase of 27728.
49%; non-net profit attributable to the parent was 15.
286 billion Yuan, a year-on-year increase of 319,397.
92%
.
Among them, in the first quarter, the company achieved a net profit of 14.
312 billion yuan, a year-on-year increase of 37527.
35%
.
For the reason for the surge in performance in the first half of the year, Jiu'an Medical attributed it to the substantial growth in demand for antigen detection kit products in the United States
.
The company stated that its own brand "iHealth" conducts TOC sales through the website of its US subsidiary and Amazon's US e-commerce platform, and undertakes government orders and commercial orders
.
Due to the substantial increase in sales revenue of iHealth kit products during the reporting period, the company's performance during the reporting period also increased significantly compared with the same period last year
.
It is reported that iHealth received an emergency use authorization (EUA) in the United States in November 2021 and started sales
.
While Jiu'an Medical achieved outstanding performance, the stock price also rose.
The day after the interim report was disclosed, the stock price rose 8.
28% to close at 53.
35 yuan per share, with a total market value of 25.
685 billion yuan, an increase of 1.
965 billion yuan that day
.
It is worth mentioning that there is a huge gap between the second quarterly report and the first quarterly report
.
In this regard, Jiu'an Medical also issued a risk warning in the interim report, and uncertainty in the future may greatly affect the demand for kit products
.
The industry believes that this means that Jiu'an Medical, which relies heavily on the overseas business of iHealth kits, will experience weak growth in the company's performance once the order is fulfilled or there is no new major operating contract
.
The industry said that in recent years, domestic IVD companies have developed rapidly due to the impact of the environment, and the entire in vitro diagnostic industry has ushered in dividends.
The performance of Zan, Wanfu Bio, Wantai Bio, and Mingde Bio continued to rise sharply, but the growth rate of some companies has experienced a significant decline compared with the same period of the previous year, especially the related detection reagent products.
Products are more obvious, and the fatigue is gradually showing.
For example, ST Kehua, Rejing Bio, and Oriental Bio, the net profit attributable to shareholders of listed companies decreased by 90.
31%, 43.
17%, and 19.
23% year-on-year respectively
.
It is reported that under the current background, many enterprises have already accelerated their transformation, focusing on optimizing product structure and technologically superior products
.
For example, Shengxiang Bio has continuously expanded its product line based on its own research and development advantages in molecular diagnostic products; Wanfu Bio has wholly acquired Tianshen Medical based on the POCT concept to improve its product line in Xiaoguang, through the combination of products and channels , in order to play a better effect; Mingde Bio responded to investors on the interactive platform on September 6, saying that with the end of the epidemic in the future, the company's other business segments will recover demand, and the company's strategic focus will be readjusted to other than testing reagents.
Business sectors, including but not limited to immunodiagnosis, molecular diagnosis, blood gas diagnosis, coagulation diagnosis, etc.
, the above sectors are expected to bring new growth points for the company
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
